Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies (NYSE/TSX: BHC) announced on October 29, 2020, that the FDA granted Orphan Drug Designation to rifaximin for treating sickle cell disease, which affects around 100,000 Americans. This designation encourages the development of treatments for rare diseases. Early data indicates rifaximin may reduce vaso-occlusive crises in sickle cell patients. The company plans to start a Phase 2 trial in 2021 to evaluate a novel rifaximin formulation for this patient population.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is set to redeem a total of $150 million of its senior notes on Nov. 30, 2020. This includes $100 million of 5.875% Senior Notes and $50 million of 5.50% Senior Notes, all funded through cash generated from operations. This move aims to decrease the company’s debt profile significantly. The redemption notices will be sent to record holders, while payments will be processed via the Depository Trust Company.
Bausch + Lomb has launched the SimplifEYE™ intraocular lens (IOL) delivery system, exclusive to the enVista® MX60PL and MX60PT lenses, marking the first preloaded toric lens available in the United States. This system enhances surgical efficiency and reduces handling risks. The enVista lenses feature a wide range of powers, excellent rotational stability, and StableFlex™ technology for improved optic recovery. This innovation underscores Bausch Health's commitment to meet evolving surgical needs.
Bausch Health Companies (NYSE/TSX: BHC) and Ortho Dermatologics will present nine posters at the virtual Fall Clinical Dermatology Conference from Oct. 29 - Nov. 1, 2020. The presentations include new analyses on ARAZLO™, DUOBRII®, SILIQ®, and pediatric data on JUBLIA®. Bill Humphries, president of Ortho Dermatologics, emphasized their commitment to addressing various skin conditions through research. The conference highlights the latest data on acne and psoriasis treatments, showcasing their extensive dermatology portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology unit, Salix Pharmaceuticals, will present 11 scientific posters at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting from October 23-28, 2020. These presentations highlight clinical data across Salix's portfolio, emphasizing their commitment to gastrointestinal health. Key topics include the efficacy of Rifaximin, Plecanatide, Methylnaltrexone, and NER1006. Robert Spurr, president of Salix, expressed enthusiasm for collaboration with healthcare professionals at this significant conference.
Bausch Health has strengthened its focus on myopia research through an exclusive license agreement with BHVI for myopia control contact lenses. This partnership aims to develop lenses that may slow myopia progression in children, addressing a growing global health issue projected to affect 50% of the population by 2050. Earlier, Bausch + Lomb secured another licensing agreement with Eyenovia for a pediatric myopia treatment. CEO Joseph C. Papa emphasizes the commitment to innovative solutions for this increasing ocular disorder.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology division, Salix Pharmaceuticals, will present five scientific posters at the United European Gastroenterology (UEG) Week Virtual 2020 from Oct. 11-13, 2020. The presentations focus on innovative treatments addressing gastrointestinal diseases, specifically featuring studies on Rifaximin and Plecanatide related to conditions such as irritable bowel syndrome and chronic liver disease. Salix's commitment to research underscores its role as a leader in gastroenterology and aims to provide valuable insights for healthcare providers.
Bausch Health Companies Inc. (NYSE/TSX: BHC) provided a preliminary update on its third-quarter 2020 results, anticipating revenues exceeding $2.1 billion, a 28% sequential increase from Q2 2020. Despite this growth, revenue is expected to decline about 3% compared to Q3 2019. For the full year, the company estimates revenues between $7.80 and $8.00 billion, with Adjusted EBITDA expected between $3.15 and $3.30 billion.
Full financial results will be released on Nov. 3, 2020, along with a conference call.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its Bausch + Lomb INFUSE™ silicone hydrogel daily disposable contact lenses will be featured in three poster presentations during the virtual American Academy of Optometry Annual Meeting from Oct. 7-22, 2020. The company has received positive feedback for the lenses since their launch in August, highlighting their comfort and performance. The research will cover various assessments, including the lens's dehydration resistance and its ability to mitigate contact lens dryness, aiming to enhance wearer experience.
Bausch Health Companies Inc. (BHC) announced the launch of LiverHEalthNow, an online resource aimed at improving the detection and management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients. This initiative coincides with Liver Awareness Month and aims to educate healthcare providers and patients. Approximately 30 million Americans are affected by liver disease, with OHE being a severe complication. Salix Pharmaceuticals, part of Bausch Health, emphasizes the importance of early detection to improve patient outcomes and reduce hospital readmissions.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
